NRG
40
5
DHR
70
2
RSG
47
2
IP
37
7
MKC
39
3
PLD
48
3
AA
72
2
PNC
67
-4
LB
29
11
FOXA
59
-5
GIS
41
3
TGT
52
-2
CTAS
39
2
ADBE
47
-3
COP
51
-2
MAS
60
2
NOC
69
6
PPL
57
-3
XEL
60
7
NTAP
45
2
NRG
40
5
DHR
70
2
RSG
47
2
IP
37
7
MKC
39
3
PLD
48
3
AA
72
2
PNC
67
-4
LB
29
11
FOXA
59
-5
GIS
41
3
TGT
52
-2
CTAS
39
2
ADBE
47
-3
COP
51
-2
MAS
60
2
NOC
69
6
PPL
57
-3
XEL
60
7
NTAP
45
2
Financhill
Back

Catalyst Pharmaceuticals, Inc. Stock Predictions

Meet America's Newest $1B Unicorn

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at
Buy
62

CPRX
Catalyst Pharmaceuticals, Inc.

Last Price:
$22.71
Seasonality Move:
9.34%

7 Day Trial

ALL ACCESS PASS

$ 7

The Next Gold Rush

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at

Catalyst Pharmaceuticals, Inc. Stock Forecast

  • Over the next 52 weeks, Catalyst Pharmaceuticals, Inc. has on average historically risen by 37.6% based on the past 19 years of stock performance.
  • Catalyst Pharmaceuticals, Inc. has risen higher in 8 of those 19 years over the subsequent 52-week period, corresponding to a historical accuracy of 42.11%
  • Is Catalyst Pharmaceuticals, Inc. Stock Undervalued?
    The current Catalyst Pharmaceuticals, Inc. [CPRX] share price is $22.72. The Score for CPRX is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.
  • CPRX is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.

Will Catalyst Pharmaceuticals, Inc. Stock Go Up Next Year?

  • Over the next 52 weeks, Catalyst Pharmaceuticals, Inc. has on average historically risen by 37.6% based on the past 19 years of stock performance.

Catalyst Pharmaceuticals, Inc. Stock Rating

Buy
62
Catalyst Pharmaceuticals, Inc. (CPRX) is a Buy

Is Catalyst Pharmaceuticals, Inc. overpriced?

  • Catalyst Pharmaceuticals, Inc. has risen higher in 8 of those 19 years over the subsequent 52-week period, corresponding to a historical accuracy of 42.11%

Catalyst Pharmaceuticals, Inc. Stock Price History

Is CPRX stock going to rise?

  • The current trend is moderately bearish and CPRX is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
catalystpharma.com

52-Week Data

52-Week High:
26.58
52-Week Low:
19.05

Prediction Charts

Market Cap:
2.8B
Price in USD:
22.72
Volume:
1.4M
Beta:
1.05

Technical Analysis

SMA50:
22.88
SMA100:
21.61
SMA200:
22.22
52-Wk Change:
-0.35%

Stock Predictions

  • Is Catalyst Pharmaceuticals, Inc. stock public?
    Yes, Catalyst Pharmaceuticals, Inc. is a publicly traded company.
  • What is the Catalyst Pharmaceuticals, Inc. stock quote today?
    The Catalyst Pharmaceuticals, Inc. stock price is 22.72 USD today.
  • How to buy Catalyst Pharmaceuticals, Inc. stock online?
    You can buy Catalyst Pharmaceuticals, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-18 23.93 23.67 24.04 23.44
Dec-19 23.80 23.74 24.22 23.67
Dec-22 23.74 24.31 24.51 23.53
Dec-23 24.31 24.23 24.59 24.04
Dec-24 24.29 24.45 24.45 24.19
Dec-26 24.38 24.35 24.44 24.08
Dec-29 24.35 24.06 24.45 23.98
Dec-30 23.91 23.29 24.25 23.21
Dec-31 23.30 23.34 23.58 23.21
Jan-5 23.02 22.80 23.10 22.29
Jan-6 22.59 22.58 22.69 22.15
Jan-7 22.85 22.72 23.43 22.53
Jan-8 22.57 22.60 22.95 22.45
Jan-9 22.72 22.72 23.17 22.63

Catalyst Pharmaceuticals, Inc. Earnings

Catalyst Pharmaceuticals, Inc. Earnings Report: Per Share Catalyst Pharmaceuticals, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Catalyst Pharmaceuticals, Inc. Forecast Revenue Growth

Catalyst Pharmaceuticals, Inc. Stock Analysis: Historical quarterly revenues per share for Catalyst Pharmaceuticals, Inc. and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.13 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.05 per share, and an increase next year of $0.04 per share.

* Catalyst Pharmaceuticals, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.